Promising combo may turn inoperable esophageal cancer into operable disease
NCT ID NCT07039162
First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tests whether adding the immunotherapy drug tislelizumab to standard chemoradiation can shrink advanced esophageal cancer enough to allow surgery. About 45 adults with unresectable esophageal squamous cell carcinoma will receive the combination, then possibly undergo surgery if the tumor becomes removable. The main goal is to see how many patients are alive after 2 years, with secondary focus on complete tumor disappearance and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, 404, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kaohsiung Chang Gung Memorial Hospital
NOT_YET_RECRUITINGKaohsiung City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
NOT_YET_RECRUITINGKaohsiung City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linkou Chang Gung Memorial Hospital
NOT_YET_RECRUITINGTaoyuan, 33305, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cheng Kung University Hospital
NOT_YET_RECRUITINGTainan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
NOT_YET_RECRUITINGTaipei, 100225, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taichung Veterans General Hospital
NOT_YET_RECRUITINGTaichung, 407219, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Veterans General Hospital
NOT_YET_RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.